Torcetrapib: una perspectiva histórica | Clínica e Investigación en Arteriosclerosis

Información del artículo

Resumen

Diversos estudios experimentales han demostrado que las lipoproteínas de alta densidad (HD L) representan un grupo funcionalmente muy heterogéneo de partículas con diversos efectos antioxidantes, antiinflamatorios, que les confiere propiedades antiaterogénicas y antitrombóticas. En la actualidad, se dispone de potentes alternativas terapéuticas que permiten alcanzar cifras muy bajas de colesterol unido a lipoproteínas de baja densidad, y desde hace varios años están en continuo desarrollo y evaluación fármacos que permiten incrementos significativos de los valores de colesterol unido a HDL, con la intención de mejorar el perfil cardiovascular de los pacientes. Los inhibidores de la enzima colesteroléster transferasa constituyen una opción terapéutica válida para este fin. A continuación se revisan los resultados de los primeros y principales ensayos clínicos que evalúan la eficacia de uno de estos fármacos (torcetrapib) así como los análisis pormenorizados realizados posteriormente por sus principales autores de las posibles explicaciones de los resultados clínicos desfavorables de éstos.

Palabras clave:

Torcetrapib

HDL

Inhibidores de la enzima colesterol-éster transferasa

Abstract

Several experimental studies have shown that high-density lipoproteins are functionally a highly heterogeneous group of particles with varied antioxidant and antiinflammatory effects, conferring them with antiatherogenic and antithrombotic properties. Potent therapeutic alternatives are currently available that allow very low values of low-density lipoprotein to be achieved. For several years, drugs that allow significant increases in high-density lipoprotein cholesterol levels have been under continuous development and evaluation, with the aim of improving patients’ cardiovascular profiles. Cholesteryl ester transfer protein inhibitors are a suitable therapeutic option for this aim. We review the results of the first and main clinical trials evaluating the efficacy of one of these drugs (torcetrapib) as well as the detailed analyses subsequently performed by their main authors of the possible explanations for the unfavorable clinical results of these trials.

Keywords:

Torcetrapib

HDL

Cholesteryl ester transfer protein inhibitors

El Texto completo está disponible en PDF

Bibliografía

[1.]

P. Barter, A.M. Gotto, J.C. LaRosa, J. Maroni, M. Szarek, S.M. Grundy, For the Treating to New Targets Investigators, et al.

HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events.

N Engl J Med, 357 (2007), pp. 1301-1310

http://dx.doi.org/10.1056/NEJMoa064278 | Medline

[2.]

P.J. Barter, J.J. Kastelein.

Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.

J Am Coll Cardiol, 47 (2006), pp. 492-499

http://dx.doi.org/10.1016/j.jacc.2005.09.042 | Medline

[3.]

S.M. Boekholdt, O.W. Souverein, M.W. Tanck, G.K. Hovingh, J.A. Kuivenhoven, R.I. Peters, et al.

Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels.

Clin Genet, 69 (2006), pp. 263-270

http://dx.doi.org/10.1111/j.1399-0004.2006.00578.x | Medline

[4.]

G.J. De Grooth, J.A. Kuivenhoven, A.F. Stalenhoef, J. De Graaf, A.H. Zwinderman, J.L. Posma, et al.

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.

Circulation, 105 (2002), pp. 2159-2165

Medline

[5.]

J.M. McKenney, M.H. Davidson, C.L. Shear, J.H. Revkin.

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below average high-density lipoprotein cholesterol levels on a background of atorvastatin.

J Am Coll Cardiol, 48 (2006), pp. 1782-1790

http://dx.doi.org/10.1016/j.jacc.2006.06.066 | Medline

[6.]

L.A. Morehouse, E.D. Sugarman, P.A. Bourassa, T.M. Sand, F. Zimetti, F. Gao, et al.

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits.

J Lipid Res, 48 (2007), pp. 1263-1272

http://dx.doi.org/10.1194/jlr.M600332-JLR200 | Medline

[7.]

R.W. Clark, T.A. Sutfin, R.B. Ruggeri, A.T. Willaver, A.D. Sugarman, G. Magnus-Arytey, et al.

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.

Arterioscler Thromb Vasc Biol, 24 (2004), pp. 490-497

http://dx.doi.org/10.1161/01.ATV.0000118278.21719.17 | Medline

[8.]

M. Guerin, W. Le Goff, E. Duchene, Z. Julia, T. Nguyen, T. Thuren, et al.

Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.

Arterioscler Thromb Vasc Biol, 28 (2008), pp. 148-154

http://dx.doi.org/10.1161/ATVBAHA.107.151688 | Medline

[9.]

M.H. Davidson, J.M. McKenney, C.L. Shear, J.H. Revkin.

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.

J Am Coll Cardiol, 48 (2006), pp. 1774-1781

http://dx.doi.org/10.1016/j.jacc.2006.06.067 | Medline

[10.]

A.R. Tall, L. Yvan-Charvet, N. Wang.

The failure of torcetrapib: was it the molecule or the mechanism?.

Arterioscler Thromb Vasc Biol, 27 (2007), pp. 257-260

http://dx.doi.org/10.1161/01.ATV.0000256728.60226.77 | Medline

[11.]

J.J. Kastelein, S.I. Van Leuven, L. Burgess, G.W. Evans, J.A. Kuivenhoven, P.J. Barter, For the RADIANCE 1 Investigators, et al.

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

N Engl J Med, 356 (2007), pp. 1620-1630

http://dx.doi.org/10.1056/NEJMoa071359 | Medline

[12.]

M.L. Bots, F.L. Visseren, G.W. Evans, W.A. Riley, J.H. Revkin, C.H. Tegeler, For the RADIANCE 2 Investigators, et al.

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

Lancet, 370 (2007), pp. 153-160

http://dx.doi.org/10.1016/S0140-6736(07)61088-5 | Medline

[13.]

S.E. Nissen, J.C. Tardif, S.J. Nicholls, J.H. Revkin, C.L. Shear, W.T. Duggan, et al.

Effect of torcetrapib on the progression of coronary atherosclerosis.

N Engl J Med, 356 (2007), pp. 1304-1316

http://dx.doi.org/10.1056/NEJMoa070635 | Medline

[14.]

P. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, M. Komadja, For the ILLUMINATE Investigators, et al.

Effects of torcetrapib on morbidity and mortality in patients at high risk for coronary events.

N Engl J Med, 357 (2007), pp. 2109-2122

http://dx.doi.org/10.1056/NEJMoa0706628 | Medline

[15.]

P. Barter.

Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial.

Am J Cardiol, 104 (2009), pp. 10E-15E

http://dx.doi.org/10.1016/j.amjcard.2009.09.014 | Medline

[16.]

C. Shear, M. Beltangady, W. Ports, W. Duggan, P. Barter.

Torcetrapib: predictors of increased clinical risk in the ILLUMINATE study.

Circulation, 118 (2008), pp. S370-S371

[17.]

M. Vergeer, M.L. Bots, S.I. Van Leuven, D.C. Basart, E.J. Sijbrands, G.W. Evans, et al.

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.

Circulation, 118 (2008), pp. 2515-2522

http://dx.doi.org/10.1161/CIRCULATIONAHA.108.772665 | Medline

[18.]

S.J. Nicholls, E.M. Tuzcu, D.M. Brennan, J.C. Tardif, S.E. Nissen.

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).

Circulation, 118 (2008), pp. 2506-2514

http://dx.doi.org/10.1161/CIRCULATIONAHA.108.790733 | Medline

[19.]

L. Yvan-Charvet, F. Matsuura, N. Wang, M.J. Bamberger, T. Nguyen, F. Rinninger, et al.

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

Arterioscler Thromb Vasc Biol, 27 (2007), pp. 1132-1138

http://dx.doi.org/10.1161/ATVBAHA.106.138347 | Medline

[20.]

M.E. Brousseau, E.J. Schaefer, M.L. Wolfe, L.T. Bloedon, A.G. Digenio, R.W. Clark, et al.

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

N Engl J Med, 350 (2004), pp. 1505-1515

http://dx.doi.org/10.1056/NEJMoa031766 | Medline

[21.]

B. Farrell, J. Godwin, S. Richards, C. Warlow.

The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.

J Neurol Neurosurg Psychiatry, 54 (1991), pp. 1044-1054

Medline

[22.]

S. Lewington, R. Clarke, N. Qizilbash, R. Peto, R. Collins.

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Lancet, 360 (2002), pp. 1903-1913

Medline

[23.]

M.J. Forrest, D. Bloomfield, R.J. Briscoe, P.N. Brown, A.M. Cumiskey, J. Ehrhart, et al.

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.

Br J Pharmacol, 154 (2008), pp. 1465-1473

http://dx.doi.org/10.1038/bjp.2008.229 | Medline

Indexada en:

Síguenos:

Suscribirse:

Indexada en:

Síguenos:

Suscribirse:

Suscríbase a la newsletter